Stimuli-Responsive Mesoporous Silica NPs as Non-viral Dual siRNA/Chemotherapy Carriers for Triple Negative Breast Cancer  Behrad Darvishi, Leila Farahmand,

Slides:



Advertisements
Similar presentations
Rhiana Lau MMG C174 Professor Simpson
Advertisements

Vaccines and Antivirals. Clinical Use of Interferon Therefore they have been used in the treatment of cancers of various types. Therefore they have been.
NAi_transcription_vo1-lg.mov.
RNA interference Definition: RNA interference (RNAi) is a mechanism where the presence of certain fragments.
SiRNA and Epigenetic Asma Siddique Saloom Aslam Syeda Zainab Ali.
Carly Sproule BE  Mechanism that silences a gene so that the protein associated with it is not expressed  Regulates gene expression  Used as.
Chapter 25 The RNA World. microRNA Previously thought to be “junk” DNA – Now determined to “code” for other RNA ENCODE project Andrew Fire and Craig Mello.
Transcription … from DNA to RNA.
Patenting Interfering RNA John LeGuyader – SPE Art Unit 1635 (571)
The Central Dogma of Molecular Biology replication transcription translation.
Ch 16. Posttranscriptional Regulation RNA interference (RNAi)
RNAi Overview
From: Emerging Roles for MicroRNAs in Perioperative Medicine
Figure 2 Dicer and RISC (RNA-induced silencing complex).
Figure Legend: From: Noncoding RNAs:New Players in Chronic Pain
A-LEVEL BIOLOGY RNA interference (RNAi)
Stimuli-Responsive Mesoporous Silica NPs as Non-viral Dual siRNA/Chemotherapy Carriers for Triple Negative Breast Cancer  Behrad Darvishi, Leila Farahmand,
Chapter 18 Gene Expression.
Steps in microRNA gene silencing
Volume 107, Issue 7, Pages (December 2001)
Genome-editing Technologies for Gene and Cell Therapy
Virginia J. Bruce, Brian R. McNaughton  Cell Chemical Biology 
Rhiana Lau MMG C174 Professor Simpson
New Hope for a MicroRNA Therapy for Liver Cancer
Knocking out the Argonautes
Profiling the Mismatch Tolerance of Argonaute 2 through Deep Sequencing of Sliced Polymorphic Viral RNAs  Pantazis I. Theotokis, Louise Usher, Christopher.
RNA Interference in Mammals: The Virus Strikes Back
RNA Interference in Mammals: The Virus Strikes Back
Rafael Kramann, Marcus J. Moeller  Kidney International 
RNA interference: the new somatic cell genetics?
Short small-interfering RNAs produce interferon-α-mediated analgesia
Molecular Therapy - Nucleic Acids
In Vivo Gene Delivery by Nonviral Vectors: Overcoming Hurdles?
Ella H. Sklan, Jeffrey S. Glenn  Gastroenterology 
Volume 59, Issue 1, Pages (July 2015)
P Bodies and the Control of mRNA Translation and Degradation
Exosomes in liver pathology
Volume 26, Issue 2, Pages (February 2018)
Gene Therapy for Autosomal Dominant Disorders of Keratin
RNA interference: It's a small RNA world
Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR
Volume 17, Issue 3, Pages (March 2015)
Molecular Therapy - Nucleic Acids
Translation From RNA to Protein.
RNAi: Prokaryotes Get in on the Act
Emerging treatments for amyloidosis
Genome-editing Technologies for Gene and Cell Therapy
The Evolution of Antiviral Defense Systems
Volume 134, Issue 4, Pages (August 2008)
Molecular Therapy  Volume 20, (May 2012) DOI: /S (16)
Gyongyi Szabo, Peter Sarnow, Shashi Bala  Journal of Hepatology 
siRNA Versus miRNA as Therapeutics for Gene Silencing
Knocking down Disease with siRNAs
Antigen Processing and Presentation
Zhao Zhang, Yuelin Zhang, Fei Gao, Shuo Han, Kathryn S
RNA Quality Control in Eukaryotes
Molecular Therapy - Nucleic Acids
Dicers at RISC Cell Volume 117, Issue 1, Pages 1-3 (April 2004)
Linking Retroelements to Autoimmunity
Molecular Therapy - Nucleic Acids
In This Issue Molecular Therapy Volume 16, Issue 4, (April 2008)
Erica E. Marsh, M. D. , Zhihong Lin, Ph. D. , Ping Yin, Ph. D
Pok Kwan Yang, Mitzi I. Kuroda  Cell 
Viral Suppressors of RNA-Based Viral Immunity: Host Targets
Increased understanding leads to increased complexity: Molecular mechanisms of pulmonary arterial hypertension  Victor A. Ferraris, MD, PhD  The Journal.
Markus Bitzer, Iddo Z. Ben-Dov, Thomas Thum  Kidney International 
Engineering parathyroid cells to treat secondary hyperparathyroidism
773. Detection of RNA Interference (RNAi) Mediated mRNA Cleavage in Fresh Injected Tumor Tissue from Patients in a Phase I Trial of pbi-shRNA™ Lipoplex.
740. Prevention of Radiation-Induced Lung Injury by Administration of Gene-Modified Mesenchymal Stem Cells    Molecular Therapy  Volume 20, Pages S285-S286.
The Power of “Genetics”
Presentation transcript:

Stimuli-Responsive Mesoporous Silica NPs as Non-viral Dual siRNA/Chemotherapy Carriers for Triple Negative Breast Cancer  Behrad Darvishi, Leila Farahmand, Keivan Majidzadeh-A  Molecular Therapy - Nucleic Acids  Volume 7, Pages 164-180 (June 2017) DOI: 10.1016/j.omtn.2017.03.007 Copyright © 2017 The Author(s) Terms and Conditions

Figure 1 RNAi Induced by siRNA At the beginning of RNA interference process, through the activity of specific nucleases known as Dicers, siRNAs are transferred to specific ribonucleoprotein complexes referred to as RISCs. Transfer of siRNAs results in activation of RISCs, which, in turn, by means of an RNA helicase enzyme, induces unrolling of the double-stranded fragments. The antisense strand, in the next step, guides the RISC-siRNA complex to the complementary target mRNA. Finally, as the complex binds with the complementary mRNA, endonucleases in the RISC complex initiate the degradation process which is then continued by endonucleases in the cytosol, resulting in complete degradation of mRNAs complementary to the siRNA. Molecular Therapy - Nucleic Acids 2017 7, 164-180DOI: (10.1016/j.omtn.2017.03.007) Copyright © 2017 The Author(s) Terms and Conditions

Figure 2 The Fate of MSNs in Cells After internalization, MSN-NPs are translocated to sorting endosomes. In next step, part of the sorting endosomes turn back to the cell’s exterior, and the remaining shift into secondary endosomes that are then fused with lysosomes. Modified MSNs effectively evade endolysosomes and enter the cytosolic compartment, where their cargos are released, and the RNAi process is begun. Molecular Therapy - Nucleic Acids 2017 7, 164-180DOI: (10.1016/j.omtn.2017.03.007) Copyright © 2017 The Author(s) Terms and Conditions

Figure 3 Conventional Stimulus-Responsive Capped MSNs Molecular Therapy - Nucleic Acids 2017 7, 164-180DOI: (10.1016/j.omtn.2017.03.007) Copyright © 2017 The Author(s) Terms and Conditions

Figure 4 New-Generation MSNs Molecular Therapy - Nucleic Acids 2017 7, 164-180DOI: (10.1016/j.omtn.2017.03.007) Copyright © 2017 The Author(s) Terms and Conditions